Market Overview

Janney Capital Downgrades AMAG Pharmaceuticals to Neutral, Maintains $20 PT


This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Latest Ratings for AMAG

Aug 2018B. Riley FBRMaintainsBuyBuy
Aug 2018Cantor FitzgeraldMaintainsNeutralNeutral
Jun 2018B. Riley FBRUpgradesNeutralBuy

View More Analyst Ratings for AMAG
View the Latest Analyst Ratings

Posted-In: News Downgrades Analyst Ratings


Related Articles (AMAG)

Affimed Shares Slide On Updated Hodgkin Lymphoma Drug Combo Data

Wall Street Reacts After Adobe Posts Q2 Earnings Beat